Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 2/20 | 0.38 |
| ▸ | CHIT1 | Q13231 | 2/20 | 0.37 |
| ▸ | DPP4 | P27487 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 4/20 | 0.32 |
| ▸ | CA2 | P00918 | 4/20 | 0.32 |
| ▸ | CA4 | P22748 | 4/20 | 0.32 |
| ▸ | CA9 | Q16790 | 4/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16644695 | 0.94 | CHIT1 (0.37) | FOLH1CHIT1DPP4CA1CA2 | |
| SCHEMBL9906195 | 0.94 | CHIT1 (0.37) | FOLH1CHIT1DPP4CA1CA2 | |
| SCHEMBL16642308 | 0.88 | CHIT1 (0.37) | FOLH1CHIT1DPP4 | |
| SCHEMBL19157450 | 0.88 | FOLH1 (0.37) | FOLH1CHIT1DPP4SLC6A9 | |
| SCHEMBL16640623 | 0.86 | CHIT1 (0.37) | FOLH1CHIT1DPP4CA1CA2 | |
| SCHEMBL9906207 | 0.86 | KCNJ1 (0.39) | FOLH1SIGMAR1 | |
| SCHEMBL13558123 | 0.86 | CHIT1 (0.32) | FOLH1CHIT1DPP4 | |
| SCHEMBL9906211 | 0.84 | GRIN1 (0.39) | FOLH1CHIT1DPP4 | |
| SCHEMBL1079200 | 0.84 | FOLH1 (0.45) | FOLH1CHIT1DPP4CA1CA2 | |
| SCHEMBL5864632 | 0.84 | FOLH1 (0.45) | FOLH1CHIT1DPP4CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2004642-B1 | BIFUNCTIONAL POLYAZAMACROCYCLIC CHELATING AGENTS | Nordion (Canada) Inc (CA) | 2017-07-26 | — | — | EP | disclosed |
| US-8518715-B2 | Bifunctional polyazamacrocyclic chelating agents | NORDION (CANADA) INC. (CA) | 2013-08-27 | — | — | US | disclosed |
| US-20120276001-A1 | BIFUNCTIONAL POLYAZAMACROCYCLIC CHELATING AGENTS | Nordion (Canada) Inc (CA) | 2012-11-01 | — | — | US | disclosed |
| US-8198101-B2 | Bifunctional polyazamacrocyclic chelating agents | NORDION (CANADA) INC. (CA) | 2012-06-12 | — | — | US | disclosed |
| US-8198101-B2 | Bifunctional polyazamacrocyclic chelating agents | NORDION (CANADA) INC. (CA) | 2012-06-12 | — | — | US | disclosed |
| US-20090202521-A1 | Bifunctional Polyazamacrocyclic Chelating Agents | MDS (CANADA) INC. (CA) | 2009-08-13 | — | — | US | disclosed |
| US-20090202521-A1 | Bifunctional Polyazamacrocyclic Chelating Agents | MDS (CANADA) INC. (CA) | 2009-08-13 | — | — | US | disclosed |
| WO-2007104135-A1 | BIFUNCTIONAL POLYAZAMACROCYCLIC CHELATING AGENTS | MDS (CANADA) INC. (CA) | 2007-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090202521-A1 | Bifunctional Polyazamacrocyclic Chelating Agents | LPXN, FCGRT, POLQ | FOLH1 110/4885CHIT1 228/4885DPP4 4606/4885 |
| US-20120276001-A1 | BIFUNCTIONAL POLYAZAMACROCYCLIC CHELATING AGENTS | LPXN, FCGRT, F13A1 | FOLH1 91/4885CHIT1 217/4885DPP4 4610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.